

Brian Dennis Lichty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9342669/publications.pdf>

Version: 2024-02-01

91
papers

8,264
citations

41258

49
h-index

49773

87
g-index

96
all docs

96
docs citations

96
times ranked

9013
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunological considerations for COVID-19 vaccine strategies. <i>Nature Reviews Immunology</i> , 2020, 20, 615-632.	10.6	806
2	Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. <i>Nature Medicine</i> , 2000, 6, 821-825.	15.2	742
3	VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. <i>Cancer Cell</i> , 2003, 4, 263-275.	7.7	734
4	Going viral with cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2014, 14, 559-567.	12.8	500
5	Vesicular stomatitis virus: re-inventing the bullet. <i>Trends in Molecular Medicine</i> , 2004, 10, 210-216.	3.5	278
6	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	242
7	The Murine Double-Stranded RNA-Dependent Protein Kinase PKR Is Required for Resistance to Vesicular Stomatitis Virus. <i>Journal of Virology</i> , 2000, 74, 9580-9585.	1.5	190
8	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
9	Intelligent Design: Combination Therapy With Oncolytic Viruses. <i>Molecular Therapy</i> , 2010, 18, 251-263.	3.7	177
10	Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. <i>Molecular Therapy</i> , 2007, 15, 123-130.	3.7	171
11	Targeting Tumor Vasculature With an Oncolytic Virus. <i>Molecular Therapy</i> , 2011, 19, 886-894.	3.7	149
12	Potentiating Cancer Immunotherapy Using an Oncolytic Virus. <i>Molecular Therapy</i> , 2010, 18, 1430-1439.	3.7	146
13	Maraba Virus as a Potent Oncolytic Vaccine Vector. <i>Molecular Therapy</i> , 2014, 22, 420-429.	3.7	134
14	A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication. <i>Molecular Therapy</i> , 2008, 16, 1437-1443.	3.7	121
15	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , 2015, 21, 530-536.	15.2	118
16	Cutting Edge: FimH Adhesin of Type 1 Fimbriae Is a Novel TLR4 Ligand. <i>Journal of Immunology</i> , 2008, 181, 6702-6706.	0.4	113
17	Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. <i>Molecular Therapy</i> , 2010, 18, 888-895.	3.7	109
18	HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. <i>Molecular Therapy</i> , 2013, 21, 887-894.	3.7	98

#	ARTICLE	IF	CITATIONS
19	Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus. <i>Molecular Therapy</i> , 2009, 17, 1814-1821.	3.7	95
20	Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. <i>Cancer Gene Therapy</i> , 2012, 19, 238-246.	2.2	94
21	Immunogenic HSV-mediated Oncolysis Shapes the Antitumor Immune Response and Contributes to Therapeutic Efficacy. <i>Molecular Therapy</i> , 2014, 22, 123-131.	3.7	93
22	Cigarette Smoke Impacts Immune Inflammatory Responses to Influenza in Mice. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 1342-1351.	2.5	91
23	Induction of Innate Immunity against Herpes Simplex Virus Type 2 Infection via Local Delivery of Toll-Like Receptor Ligands Correlates with Beta Interferon Production. <i>Journal of Virology</i> , 2006, 80, 9943-9950.	1.5	90
24	Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV ^{ΔM51}) on Multifocal and Invasive Gliomas. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1546-1557.	3.0	88
25	Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy. <i>Molecular Therapy</i> , 2011, 19, 335-344.	3.7	88
26	A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. <i>Molecular Therapy</i> , 2010, 18, 1123-1129.	3.7	85
27	Oncolytic Viruses: Therapeutics With an Identity Crisis. <i>EBioMedicine</i> , 2016, 9, 31-36.	2.7	82
28	Mucosal Luminal Manipulation of T Cell Geography Switches on Protective Efficacy by Otherwise Ineffective Parenteral Genetic Immunization. <i>Journal of Immunology</i> , 2007, 178, 2387-2395.	0.4	81
29	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. <i>Cancer Cell</i> , 2015, 28, 210-224.	7.7	77
30	Vesicular Stomatitis Virus: A Potential Therapeutic Virus for the Treatment of Hematologic Malignancy. <i>Human Gene Therapy</i> , 2004, 15, 821-831.	1.4	76
31	Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 5400-5410.	3.9	76
32	Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine. <i>Molecular Therapy</i> , 2012, 20, 1791-1799.	3.7	70
33	Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. <i>PLoS ONE</i> , 2016, 11, e0155947.	1.1	68
34	S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. <i>Nature Immunology</i> , 2016, 17, 514-522.	7.0	67
35	Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity. <i>Molecular Therapy</i> , 2009, 17, 1465-1472.	3.7	66
36	Human Coronavirus OC43 Nucleocapsid Protein Binds MicroRNA 9 and Potentiates NF- κ B Activation. <i>Journal of Virology</i> , 2014, 88, 54-65.	1.5	66

#	ARTICLE	IF	CITATIONS
37	FimH Can Directly Activate Human and Murine Natural Killer Cells via TLR4. <i>Molecular Therapy</i> , 2010, 18, 1379-1388.	3.7	65
38	Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy. <i>Cancer Immunology Research</i> , 2013, 1, 309-319.	1.6	62
39	Cancer immunology and canine malignant melanoma: A comparative review. <i>Veterinary Immunology and Immunopathology</i> , 2016, 169, 15-26.	0.5	62
40	Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. <i>Tuberculosis</i> , 2006, 86, 211-217.	0.8	61
41	Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease. <i>Molecular Therapy</i> , 2014, 22, 1320-1332.	3.7	60
42	ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic. <i>Molecular Therapy</i> , 2012, 20, 1148-1157.	3.7	59
43	Microvesicles: ubiquitous contributors to infection and immunity. <i>Journal of Leukocyte Biology</i> , 2015, 97, 237-245.	1.5	54
44	Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1998, 103, 711-715.	1.2	53
45	Cigarette Smoke Suppresses Type I Interferon-Mediated Antiviral Immunity in Lung Fibroblast and Epithelial Cells. <i>Journal of Interferon and Cytokine Research</i> , 2008, 28, 167-179.	0.5	53
46	Strategies to Enhance Viral Penetration of Solid Tumors. <i>Human Gene Therapy</i> , 2011, 22, 1053-1060.	1.4	53
47	Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. <i>Oncolmmunology</i> , 2019, 8, e1512329.	2.1	53
48	The p14 FAST Protein of Reptilian Reovirus Increases Vesicular Stomatitis Virus Neuropathogenesis. <i>Journal of Virology</i> , 2009, 83, 552-561.	1.5	52
49	Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 ⁺ T-cell responses to anticancer vaccines. <i>Oncolmmunology</i> , 2013, 2, e26013.	2.1	51
50	IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. <i>Cancer Research</i> , 2011, 71, 2497-2506.	0.4	49
51	Evolution of oncolytic viruses: novel strategies for cancer treatment. <i>Immunotherapy</i> , 2013, 5, 1191-1206.	1.0	49
52	Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 2668-2680.	0.6	48
53	Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. <i>JCI Insight</i> , 2022, 7, .	2.3	46
54	Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. , 2019, 7, 189.		41

#	ARTICLE	IF	CITATIONS
55	Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus- ϵ -vectored Tuberculosis Vaccine. <i>Molecular Therapy</i> , 2008, 16, 1161-1169.	3.7	40
56	IL-15 Can Signal via IL-15R α , JNK, and NF- κ B To Drive RANTES Production by Myeloid Cells. <i>Journal of Immunology</i> , 2012, 188, 4149-4157.	0.4	40
57	Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses. <i>Blood</i> , 2013, 121, 2432-2439.	0.6	36
58	Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. <i>Journal of Immunology</i> , 2016, 196, 4587-4595.	0.4	35
59	Development and applications of oncolytic Maraba virus vaccines. <i>Oncolytic Virotherapy</i> , 2018, Volume 7, 117-128.	6.0	34
60	Vesicular Stomatitis Virus Oncolytic Treatment Interferes with Tumor-Associated Dendritic Cell Functions and Abrogates Tumor Antigen Presentation. <i>Journal of Virology</i> , 2011, 85, 12160-12169.	1.5	33
61	Combining oncolytic virotherapy and tumour vaccination. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 143-148.	3.2	32
62	Customized Viral Immunotherapy for HPV-Associated Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 847-859.	1.6	32
63	RNA editing enzyme APOBEC3A promotes pro-inflammatory M1 macrophage polarization. <i>Communications Biology</i> , 2021, 4, 102.	2.0	28
64	Dysregulation of HOX11 by Chromosome Translocations in T-cell Acute Lymphoblastic Leukemia: A Paradigm for Homeobox Gene Involvement in Human Cancer. <i>Leukemia and Lymphoma</i> , 1995, 16, 209-215.	0.6	26
65	Transforming the prostatic tumor microenvironment with oncolytic virotherapy. <i>OncImmunology</i> , 2018, 7, e1445459.	2.1	26
66	Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. <i>OncImmunology</i> , 2018, 7, e1423171.	2.1	26
67	CXCR6 by increasing retention of memory CD8 ⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. , 2021, 9, e003329.		25
68	IL-15 has innate anti-tumor activity independent of NK and CD8 T cells. <i>Journal of Leukocyte Biology</i> , 2010, 88, 529-536.	1.5	23
69	Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. <i>Vaccine</i> , 2018, 36, 2181-2192.	1.7	22
70	Excipient selection for thermally stable enveloped and non-enveloped viral vaccine platforms in dry powders. <i>International Journal of Pharmaceutics</i> , 2019, 561, 66-73.	2.6	22
71	Sterile filtration of oncolytic viruses: An analysis of effects of membrane morphology on fouling and product recovery. <i>Journal of Membrane Science</i> , 2018, 548, 239-246.	4.1	20
72	Matrix protein of Vesicular stomatitis virus harbours a cryptic mitochondrial-targeting motif. <i>Journal of General Virology</i> , 2006, 87, 3379-3384.	1.3	18

#	ARTICLE	IF	CITATIONS
73	Diplomatic immunity: turning a foe into an ally. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 13-21.	2.8	18
74	Characterization of the Shope Fibroma Virus DNA Ligase Gene. <i>Virology</i> , 1994, 202, 642-650.	1.1	17
75	Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen. <i>Journal of Immunology</i> , 2010, 184, 4269-4275.	0.4	16
76	Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. , 2020, 8, e000981.		15
77	Measles Vaccines Designed for Enhanced CD8+ T Cell Activation. <i>Viruses</i> , 2020, 12, 242.	1.5	15
78	A critical role for IL-15 in TLR-mediated innate antiviral immunity against genital HSV-2 infection. <i>Immunology and Cell Biology</i> , 2011, 89, 663-669.	1.0	13
79	Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. , 2022, 10, e003923.		13
80	Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers. <i>Oncolmmunology</i> , 2021, 10, 1885778.	2.1	12
81	Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats. <i>Scientific Reports</i> , 2017, 7, 15738.	1.6	11
82	Spray dried VSV-vectored vaccine is thermally stable and immunologically active in vivo. <i>Scientific Reports</i> , 2020, 10, 13349.	1.6	11
83	Purification of therapeutic adenoviruses using laterally-fed membrane chromatography. <i>Journal of Membrane Science</i> , 2019, 579, 351-358.	4.1	10
84	Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14637-e14637.	0.8	10
85	Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination. <i>Methods in Molecular Biology</i> , 2020, 2058, 191-211.	0.4	7
86	Consecutive Spray Drying to Produce Coated Dry Powder Vaccines Suitable for Oral Administration. <i>ACS Biomaterials Science and Engineering</i> , 2018, 4, 1669-1678.	2.6	6
87	Using G-deleted vesicular stomatitis virus to probe the innate anti-viral response. <i>Journal of Virological Methods</i> , 2008, 153, 276-279.	1.0	5
88	Oncolytic viruses: a step into cancer immunotherapy. <i>Virus Adaptation and Treatment</i> , 0, , 1.	1.5	4
89	Exon-skipping in BCR/ABL is induced by ABL exon 2. <i>Biochemical Journal</i> , 2000, 348, 63.	1.7	3
90	Probing effects of additives on the filterability of oncolytic viruses via a microfiltration process. <i>Journal of Membrane Science</i> , 2021, 620, 118783.	4.1	0

#	ARTICLE	IF	CITATIONS
91	Combining Oncolytic Viruses with Cancer Immunotherapy. , 2011, , 339-355.		0